Pharmaceutical composition, methods for treating and uses thereof
AssigneeBoehringer Ingelheim International GmbH
InventorsUli Christian BROEDL, Odd-Erik JOHANSEN, Eric Williams MAYOUX, Nima SOLEYMANLOU, Maximilian von EYNATTEN, Hans-Juergen WOERLE, David Z.I. CHERNEY, Bruce A. PERKINS
Life of this patent
Estimating the term…
Abstract
The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
Claims33
1) A method of treating, preventing, protecting against, reducing the risk of, delaying the occurrence of and/or delaying the progression of chronic kidney disease in a patient, said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.
7) A method of treating, preventing, protecting against or delaying new onset of albuminuria in a patient, said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.
12) A method of treating, preventing, protecting against or delaying the progression from no albuminuria to micro- or macroalbuminuria in a patient at risk for renal disease, said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.
14) A method of treating, preventing, protecting against or delaying the progression from microalbuminuria to macroalbuminuria in a patient with chronic kidney disease, said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.
16) A method for treating, preventing, protecting against or delaying the progression of chronic kidney disease in a patient, said method administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.
19) A method of treating, preventing, protecting against or delaying the occurrence of:
- new onset of albuminuria,
- doubling of serum creatinine level accompanied by an eGFR (based on modification of diet in renal disease (MDRD) formula) ≤45 mL/min/1.73 m2,
- need for continuous renal replacement therapy, or
- death due to renal disease,
- in a patient, said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.
Dependencies are inferred from the claim text.